In contrast to supplementing FMRP protein in individuals with FXS, inhibiting the expression of FMR1 using an ASO or microRNA may be beneficial in preventing the formation and/or progression of the FMR1 mRNA inclusions in FXTAS patients [79,80,81]. This evidence concerns the gene FMR1 and fragile X-associated tremor/ataxia syndrome.